|
Resistance trend in isolates of Salmonella spp. over 5 years in Kuwait |
|||||
| Antibiotic |
Percentage (%) of resistant isolates in: |
||||
|
|
|||||
| 1999 (n = 216) |
2000 (n = 215) |
2001 (n = 129) |
2002 (n = 167) |
2003 (n = 165) |
|
|
|
|||||
| Amikacin |
0 |
0 |
0 |
0 |
0 |
| Ampicillin |
6 |
12 |
7 |
25 |
26 |
| Amoxicillin-clavulanate |
5 |
10 |
7 |
2 |
0 |
| Cefotaxime |
0 |
1 |
0 |
1 |
0 |
| Ceftriaxone |
0 |
1 |
0 |
2 |
0 |
| Cefuroxime |
1 |
1 |
0 |
27 |
41 |
| Cephalexin |
2 |
10 |
37 |
57 |
50 |
| Chloramphenicol |
8 |
21 |
0 |
18 |
18 |
| Ciprofloxacin |
0 |
0 |
14 |
10 |
16 |
| TMP/SMX |
8 |
8 |
10 |
20 |
20 |
| Gentamicin |
6 |
1 |
0 |
42 |
42 |
| Imipenem |
0 |
0 |
0 |
0 |
0 |
| Meropenem |
0 |
0 |
0 |
0 |
0 |
| Piperacillin |
6 |
13 |
13 |
23 |
25 |
| Piperacillin/tazobactam |
0 |
0 |
0 |
0 |
0 |
|
No ESBL-producing strain has been isolated so far | |||||
Zhang et al. Globalization and Health 2006 2:6 doi:10.1186/1744-8603-2-6 |
|||||